Comparison of the effects of single predonine and predonine-iguratimod therapy on the old elderly onset arthritis.randomized controlled trial. - The effects of iguratimod therapy on the elderly onset arthritis.

开始日期2016-08-01

申办/合作机构-

100 项与氢化泼尼松琥珀酸钠相关的临床结果

登录后查看更多信息

100 项与氢化泼尼松琥珀酸钠相关的转化医学

登录后查看更多信息

100 项与氢化泼尼松琥珀酸钠相关的专利（医药）

登录后查看更多信息

562

项与氢化泼尼松琥珀酸钠相关的文献（医药）

2023-10-01·Skin Health and Disease

Ganciclovir-Induced Drug Reaction with Eosinophilia and Systemic Symptoms

作者: Mizawa, Megumi ; Fujita, Kuniko ; Furukawa, Fumina ; Mori, Shuichi ; Shimizu, Tadamichi ; Makino, Teruhiko ; Kitayama, Shohei ; Kagoyama, Ko

AbstractDrug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse reaction involving multiorgan failure, with a complex interaction of various drugs, human herpesvirus reactivation and immune abnormalities suggested as the aetiology. We herein present the case of a 70-year-old man with a one-week history of fever, facial oedema, erythematous macules and purpura on his trunk and extremities. He had anti-TIF1γ antibody-positive dermatomyositis and was treated with prednisolone sodium succinate (20 mg/day). Three weeks earlier, he was treated with ganciclovir (250 mg/day) for 7 days to treat asymptomatic cytomegalovirus viraemia. Laboratory investigations revealed eosinophilia with atypical lymphocytes and elevated liver enzyme levels. A histological examination showed interface dermatitis with necrotic keratinocytes, perivascular infiltration of lymphocytes and eosinophils in the upper dermis and erythrocyte extravasation without vasculitis. A lymphocyte transformation test (LTT) was positive for ganciclovir (stimulation index: 260%; normal: <180%). We diagnosed DRESS caused by ganciclovir on the basis of clinical findings and course (Definite; RegiSCAR score: 7). He was treated with prednisolone sodium succinate (40 mg/day) and topical clobetasol propionate (0.05%) ointment twice daily. After the initiation of treatment, the skin lesions and laboratory abnormalities gradually improved. To our knowledge, this is the first case of DRESS caused by ganciclovir. The patients in whom ganciclovir is used are often immunosuppressed and may be overlooked as the causative drug for DRESS by conventional skin tests. We considered that LTT is useful for identifying causative drugs of DRESS, especially in immunosuppressed patients, such as the present case.

2023-03-01·Interventional Radiology

Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study

Article

作者: Wada, Takeshi ; Tsuchiya, Satoshi ; Aramaki, Takeshi ; Akutsu, Akira ; Uno, Takashi ; Koizumi, Jun ; Kubota, Yoshihiro ; Saiga, Atsushi ; Yokota, Hajime

PurposePostembolization syndrome (PES) after renal arterial embolization (RAE) can reduce the patient's tolerance of the procedure and extend the length of hospital stay. We aimed to assess the efficacy of steroid administration in preventing PES in patients undergoing RAE for angiomyolipoma (AML).Material and MethodsBetween May 2004 and March 2020, 29 RAE procedures in 26 patients with AML were performed. Patient information, including age, sex, tumor size, tuberous sclerosis complex-associated/sporadic AML, hemorrhagic/nonhemorrhagic AML, embolic material, steroid use, medication type, some blood laboratory parameters, hospital stay, and PES occurrence were retrospectively obtained. The prophylactic steroid protocol used in the study was as follows: 250 mg of intravenous methylprednisolone (Solu-Medrol) 2 h before the RAE procedure, followed by 2 days of intravenous prednisolone (Predonine; 2 mg/kg/day), which was tapered by halving the dose every 2 days within the course of 2 weeks. After the discharge, intravenous prednisolone was changed to oral prednisolone (Predonine). PES was defined as the presence of fever, pain, nausea, or vomiting. Data were compared between the steroid and non-steroid groups and between PES and non-PES groups.ResultsThe PES incidence rate was 76%, and a comparison between the steroid and non-steroid groups revealed that steroid use significantly decreased the incidence of PES (P < 0.001), including fever (P < 0.001), pain (P = 0.005), and nausea (P = 0.028). The use of anti-inflammatory drugs during the hospital stay was significantly lower in the steroid group (P = 0.019). Moreover, in the steroid group, C-reactive protein level was significantly lower (P = 0.006), whereas white blood cell count was significantly higher (P = 0.004). Conversely, the median length of hospital stay was not significantly shorter in the steroid group (P = 0.292).ConclusionsThe prophylactic use of steroids before and after embolization of renal AML may be effective in preventing PES in this small retrospective study.

2023-01-01·European Journal of Cancer

Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer

Article

作者: Loibl, Sibylle ; Schneeweiss, Andreas ; Heeson, Sarah ; Liu, Haiying ; Kuemmel, Sherko ; Gianni, Luca ; Tan, Antoinette R ; Swain, Sandra M ; Aguila, Christian ; Macharia, Harrison ; Yang, Ke ; Dang, Chau T ; O'Shaughnessy, Joyce ; Restuccia, Eleonora

AIMTo characterise risk of anaphylaxis/hypersensitivity with intravenous pertuzumab plus trastuzumab (PH IV), the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) or concomitant chemotherapy to support potential administration of PH FDC SC by healthcare professionals outside clinics.METHODSA cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) was performed for all pivotal trials cited in the current EMA P IV/PH FDC SC summaries of product characteristics: MBC: NCT00567190, NCT02402712; EBC: NCT01358877, NCT00545688, NCT00976989, NCT02132949, NCT03493854 and NCT03674112. Occurrence, incidence and severity of events were analysed and a time-trend analysis (by cycle) was performed.RESULTSThis analysis includes 4772 patients who received PH IV and/or PH FDC SC. Incidence of all-grade (grade ≥3) anaphylaxis/hypersensitivity events: 3-11% (≤2%) for PH IV MBC trials; 1-13% (0-3%) for PH IV EBC trials; and 2-3% (<1%; not related to PH FDC SC) for PH FDC SC EBC trials. Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two arms of TRYPHAENA: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. Time-trend analysis showed that most events were reported during the first 6-8 cycles with concurrent chemotherapy, with a decrease in later cycles (except MetaPHER).CONCLUSIONPH IV and PH FDC SC were well tolerated, with few grade ≥3 anaphylaxis/hypersensitivity events reported with PH IV and no grade ≥3 related events with PH FDC SC. Most events occurred during chemotherapy.

100 项与氢化泼尼松琥珀酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01239	氢化泼尼松琥珀酸钠	D07XA02 D07AA03 S02BA03 A07EA01 C05AA04 S03BA02 S01CB02 H02AB06 R01AD02 S01BA04	DB14633

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾上腺皮质疾病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
强直性脊柱炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
哮喘	日本	Shionogi Pharma Co., Ltd.	1960-12-24
胶原蛋白疾病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
脑脊髓炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
肉芽肿伴多血管炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
心脏衰竭	日本	Shionogi Pharma Co., Ltd.	1960-12-24
幼年特发性关节炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
白血病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
显微镜下多血管炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
多发性硬化症	日本	Shionogi Pharma Co., Ltd.	1960-12-24
重症肌无力	日本	Shionogi Pharma Co., Ltd.	1960-12-24
多发性肌炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
肺纤维化	日本	Shionogi Pharma Co., Ltd.	1960-12-24
风湿热	日本	Shionogi Pharma Co., Ltd.	1960-12-24
类风湿关节炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
系统性红斑狼疮	日本	Shionogi Pharma Co., Ltd.	1960-12-24
系统性血管炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
甲状腺疾病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
亚急性甲状腺炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MP87-07 (AUA2015)	临床2期	去势抵抗性前列腺癌	120	Intermittent Docetaxel and Prednisolone (DP)	積蓋蓋膚壓獵淵衊壓壓(遞醖壓糧鑰鬱襯繭憲艱) = 網窪鹹網壓築鏇遞艱醖繭鬱選膚鏇築顧醖鹹窪 (壓選艱糧觸廠鹹觸製淵 ) 更多	-	2015-04-01